2-Benzylidene-1-indanone derivatives as inhibitors of monoamine oxidase

This publication has 28 references indexed in Scilit:

• Improving l‐dopa therapy: The development of enzyme inhibitors
  Movement Disorders, 2014
• A neuroscientific update on monoamine oxidase and its inhibitors
  CNS Spectrums, 2013
• Inhibitor Design for Monoamine Oxidases
  Current Pharmaceutical Design, 2013
• Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
  Current Topics in Medicinal Chemistry, 2012
• Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression
  CNS Spectrums, 2012
• Protection Against Parkinson’s Disease Progression: Clinical Experience
  Neurotherapeutics, 2008
• Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
• The therapeutic potential of monoamine oxidase inhibitors
  Nature Reviews Neuroscience, 2006
• Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
  Annals of Neurology, 2002
• Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey
  1998